Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LD013 in Refractory/Relapsed Mesothelin-Positive Ovarian Cancer
NCT05372692Phase 1Completed
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LD013 in ovarian cancer. Primary endpoint: Objective Remission Rate. Started Apr 2022; status: completed.
02
Drugs
LD013
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05372692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372692.